A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer’s Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging
Manuscript Number:
19-0367R1
Author(s):
Haitham Abulaban, Ross Andel, Gary W. Arendash, John Arrington, Rob Baranowski, Lino Becerra, Chuanhai Cao, Xiaoyang Lin, Jay Moulton, Amanda Smith, Gary Wisniewski, David Wittwer, Xiaolin Zhang
Disclosures
Haitham Abulaban
Nothing to Disclose
Ross Andel
Nothing to Disclose
Gary W. Arendash
Equity:
Gary Arendash has a majority of common shares in NeuroEM Therapeutics, Inc.
Sponsors:
I am the Founder and CEO of NeuroEM Therapeutics, Inc.
John Arrington
Nothing to Disclose
Rob Baranowski
Consulting Fees:
The company that I am employed by, Left Coast Engineering, has received consulting fees from NeuroEM for a variety of services. Personally, I am on NeuroEM's advisory board in a compensated role.
Equity:
I own NeuroEM shares.
Lino Becerra
Nothing to Disclose
Chuanhai Cao
Equity:
I am a co-inventor of this technology, so I have got some entitlement to equity in NeuroEM through a license agreement.
Grants
Agency:
Dates:
Agency:
Dates:
Xiaoyang Lin
Nothing to Disclose
Jay Moulton
Nothing to Disclose
Amanda Smith
Consulting Fees:
Eisai-- advisory board for BAN-2401. Single event. $450/hr for a single day.